May 26, 2023
Symptoms of hyperoxaluria are kidney stones which are hard deposits of minerals and salts inside the kidneys, chronic kidney disease where the kidneys get damaged and urinary tract infections.
seen from Malaysia
seen from Russia
seen from United Kingdom
seen from United Kingdom
seen from United States
seen from Italy
seen from Italy
seen from Australia
seen from Russia
seen from Netherlands
seen from United States
seen from Argentina
seen from Germany
seen from China
seen from Canada
seen from Türkiye
seen from United States
seen from China
seen from Hong Kong SAR China
seen from China
Symptoms of hyperoxaluria are kidney stones which are hard deposits of minerals and salts inside the kidneys, chronic kidney disease where the kidneys get damaged and urinary tract infections.
Abstract Calcium supersaturation in urine during hyperoxaluria can lead to renal calcium oxalate (CaOx) stone deposition; a condition termed
American Kidney Fund @KidneyFund Genetic testing is an important tool in diagnosing #hyperoxaluria and other rare diseases. Thank you @OHFTweet for sharing this resource to help us learn more! https://bit.ly/VidTuesday #RaiseTheHype2021 (at Hammond, Indiana) https://www.instagram.com/p/CWlx2t8PstZ/?utm_medium=tumblr
National Kidney Foundation @nkf #DYK if you experience blood in your urine, the cause could be a kidney stone? If this happens, notify your primary care physician. Read more about diagnosing #hyperoxaluria today. #HyperoxaluriaWeek2021 #RaiseTheHype2021 #DiagnoseHyperoxaluria @OHFTweet https://hyperoxaluriaweek.ohf.org/ (at Hammond, Indiana) https://www.instagram.com/p/CWBxHZgvbiS/?utm_medium=tumblr
American Kidney Fund @KidneyFund Congratulations to @Alnylam on @US_FDA approval of this first non-surgical approved treatment for adults and children living with primary #hyperoxaluria type 1. This innovative treatment will have a tremendous impact on the #kidney and #raredisease communities. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-rare-metabolic-disorder (at Hammond, Indiana) https://www.instagram.com/p/CH_MKVpj6zf/?igshid=9ef1arw7tuv0
American Kidney Fund @KidneyFund Congratulations @OHFTweet on a successful #HyperoxaluriaWeek2020. We’re looking forward to working with you in the coming months to bring more awareness to #hyperoxaluria and we are grateful to@Alnylam for their sponsorship of our work in this space. (at Hammond, Indiana) https://www.instagram.com/p/CHqdvMyj-qL/?igshid=pqn7rutz7nqp
Global Hyperoxaluria Pipeline Review 2016 - Research And Market: Radiant Insights , Inc
Hyperoxaluria - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperoxaluria - Pipeline Review, H2 2016, provides an overview of the Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline landscape.
Hyperoxaluria is defined by the presence of excess amounts of oxalic acid (oxalate) in the urine. Symptoms include severe or sudden abdominal or flank pain, blood in the urine, fever and chills, loss of appetite, nausea and vomiting. Treatment includes a low-oxalate diet and vitamin B-6.
Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperoxaluria - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hyperoxaluria (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Hyperoxaluria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 3, 1 and 1 respectively.Hyperoxaluria.
Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
To Access Browse Full Research Report @: http://www.radiantinsights.com/research/hyperoxaluria-pipeline-review-h2-2016
Scope
The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperoxaluria (Genito Urinary System And Sex Hormones).
The pipeline guide reviews pipeline therapeutics for Hyperoxaluria (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Hyperoxaluria (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Hyperoxaluria (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Hyperoxaluria (Genito Urinary System And Sex Hormones)
Reasons To Buy
Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for Hyperoxaluria (Genito Urinary System And Sex Hormones).
Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
To access Request A Sample Copy Of This Report at: http://www.radiantinsights.com/research/hyperoxaluria-pipeline-review-h2-2016/request-sample
About Radiant Insights Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. It assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. The Organization has a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
Media Contact: Company Name: Radiant Insights, Inc Contact Person: Michelle Thoras Email: [email protected] Phone: (415) 349-0054 Address: 28 2nd Street, Suite 3036 City: San Francisco State: California Country: United States For more information, Visit: http://www.radiantinsights.com
Publisher's, "Hyperoxaluria-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Hyperoxaluria. The Publisher's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including...
ReportsWeb.com published “Hyperoxaluria Market” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.